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CHAPTER I
INTRODUCTION
Meaningful speech may be considered one of man's
greatest achievements. Speech is the most important means
by vrhich man has to interact with his environment. By this
extraordinary capacity, man has shaped the world in which he
lives. Elven the development and refinement of man's ideas
are dependent upon his ability to speak. Speech structures
our thinking and behavior.
When man speaks, he speaks with his entire body, that
is, all of the major physiological systems Interact in the
process. All these processes must enter into superb inter-
gratio.ns v/hich are correlated with previous learning. Per-
haps no other human activity requires greater co-ordination
than speaking. It is man's advanced nervous system vjhich
has made this complex speaking process possible.
The central nervous system in man holds a vital role
in his ability to speak. Without this com_plex central nerv-
ous system, man would be completely incapable of speaking.
The important anatomical units of the central nervous sys-
tem are the cerebral cortex, the cerebral ventricles, the
basal ganglia, the thalmus, the mid brain, the pons, the
medulla, the cerebellum, and the spinal cord.
Man's ability to remember and to adapt to nev/ situa-
tions is largely the result of the development of the .
2cerebral cortex. The cortex is often referred to as the
outer cover for the cerebrum and contains four lobes: fron-
tal, parietal, temporal, and occipital. The cerebral ven-
tricle's main function is to manufacture cerebrospinal fluid
which circulates through the brain and spinal cord. The
basal ganglia, located below the cerebral cortex, contains
three gray nuclear masses. This is also known as the in-
ternal capsule which controls the thousands of pathways going
to and from the cerebral cortex. The thalamus is known as
the sensory "relay station" since all visual, auditory, so-
matic, and visceral impulses end or synapse here before con-
tinuing to the cerebral cortex. Thus, this part of the brain
is sometimes called the "feeling" center of the brain. The
midbrain originates the higher centers of the brain and is
responsib;ie for the finer motor co-ordinat j on movements.
The most important bridge between the brain stem, cerebellum,
and cerebral cortex, is the pons which lies just below the
midbrain. VJithin the pons are nuclear ref].ex centers for
breathing and circulation. The medulla is an enlargement of
the upper end of the spinal cord. The pathways from the mid-
brain now split into two pyramidal tracts. The cerebellum
lies beneath the cerebrum and above the pons-medulla . The
cerebellum receives inform/ition from all parts of the body.
An extension of the medulla, the spinal cord decreases in
diam.eter as it proceeds dovjnward through the body. The
spinal cord and spinal nerves receive and transmit sensory
3impulses from the body to the brain. They assist in the
out-going impulses from the brain to the muscles of the body.
Also, they have sympathetic control of smooth muscles, cir-
culatioJi, and glandular function.
Within this complex overview of the general function-
ing of the central nervous system, specific functions are
thought to be more directly related to speech. All the
lobes of the cerebral cortex are important to speech since
any sensory or incoming stimuli may make connection vjith the
speech association areas and become part of the stimulation-
integration-response arc of speech. The cerebral cortex has
certain receptive areas that are significant for speech.
The auditory receptive areas are located along the fissure
of Sylvius and extend into the parietal lobe. When these
receptive areas are intact, the individual can perceive
speech sounds and is able to understand their meanings. The
areas beliind the fissure of Rolando makes possible the sense
of touch and muscle movement, thus permitting precise tongue
movements necessary for speech. Also in the cerebral cortex,
is Broca's area with many underlying connecting fibers that
control the muscles of speech. Related areas include memory,
past experience, reasoning, and abstract thinking, which are
all necessary in the total speech arc. The cerebral cortex,
the basal ganglia, and the thalamus, which pertain to the
speech arc, probably act as one unit. The midbrain acts as
a "relay station" for hearing. Perception of loudness comes
- 5r 4 ' f
from this area as well. The pons supplies a passagev;ay for
the sensory and Tiotor pathvmys . The breathing rhythm, eon-
trolled by the medulla, becomes more dominant during speak-
ing than in normal breathing. The cerebellum is of great
importance to speech because it is the area of control of
voli^ntarjf muscle movement. The sensory impulses from the
body are transmitted through fiber bundles in the spinal
cord. Some of these fibers \^iill end in the cerebellum and
thalamus and may effect the speech response either directly
or indirectly.
The chemical compound magnesium pemoline, produced
by Abbott Laboratories under the trade name Cylert, has been
introduced as a central nervous system stimulant. Cylert is
a combination of pemoline and magnesium hydroxide. This com-
pound apparently stimulates the production or RNA, which in
turn, stimulates the centra] nervous system. As discussed
previously?, the central nervous system controls the ability
to produce meaningful speech. Therefore, the enhancement
or stimulation of the central nervous system should facili-
tate this activity.
Magnesium pemoline has been shown to im.prove learning
and retention ability in experimental animals.' It is not
fully understood hovr this chemical actually works, but the
K. Plotnikoff, "Magnesium Pemoline: Enhancement of
Learning and Memory of a Conditioned Avoidance Response,"
Science ^ 1^1 (February 11, 1966), 703-70l|.
predominant assumption is that Cylort has an ability to stim-
ulate RNA polymerase. According to Glasky and Simon, magne-
sium pemoline facilitates the synthesis of nucleic acids in
2the brains of rats which enhances memory and learning. In
accordance with Glasky and Simon's biochemical findings, is
the behavioral evidence of Plotnikoff v;ho reports that mag-
nesium pemoline facilitates the learning of a simple avoid-
ance response in rats selected as "slow learners."
In addition to these experiments with animals, human
subjects have been treated with magnesium pemoline. Cameron
has indicated that magnesium pemoline improves the memory of
older patients suffering from intellective deterioration.
Burns, House, Fench, and Miller have found that in a normal
population of young adults, magnesium pemoline did not facil-
5Itate learning. Magnesium pemoline has been found to exert
a general alerting or anti-fatigue effect in a study done by
2
A. V. Glasky and L. E. Simon, "Magnesium Pemoline:
Enhancement of Brain RNA Polymerases," Science. Vjl (Feb-
ruary 11, 1966), 701-703.
^Plotnikoff, o£. cit.. p. 703.
^D. E. Cameron, "The Use of Nucleic Acid in Aged
Patients with Memory Impairment," Journal of American Medical
Association
. 196 (29, 1966), ij.01
.
J. Burns, R. House, F. Fench, and J. Miller, "Effects
of Magnesium Pemoline and Dextroamphetamine on Human Learn-
ing," Science
.
l55 (February 17, 1967), 8ij.9-85l.
Lienert and Janke. Cameron, who has claimed to help pa-
tients with a severe memory deficit by orally administering
RNA, has reported a similar success as a result of magnesium
pemoline treatment. Several of his amnesic patients have
improved their scores on V/echsler's Memory Quotient Test
after prolonged medication with Cylert. Talland, Hagon, and
James have tested the performance on the acquisition of new
information and on its recall in chronic Korsakoff patients
VJho had received Cylert.
At the Veteran's Administration Hospital in Topeka,
Kansas; Foster, Wing, and Goldstein are engaged in research
using magnesium pemoline as an enhancer of memory and learn-
9ing abilities in brain damaged patients. These researchers
have found some preliminary evidence that magnesium pemoline
has increased the memory and learning span of some of these
patients. These promising results suggest that further
G. A, Lienert, and W. Janke, "Pharmacologische
Untersuchungen Uber 5-Phenyl-iminno-oxo-oxazotidine ,
"
Arzneimittel-Forsch, 7 (March, 1957), )+36-)|39.
D. E. Cameron and S. Sved, "Ribonucleuic Acid and
Psychiatric Therapy," Current Psychiatric Therapies , )|
(196[^), 127-133. " - - - - .
G. Talland, D. Hagen, and M. James, "Performance
Tests of Amnesic Patients with Cylert," The Journa l of Nerv -
dus and Mental Disease. ll\k (5, 1967), U21-l|-29.
^R. Foster, N. Ming, and J. Goldstein, "The Use of
Magnesium Pemoline as an Enhancer of Memory and Learning
Abilities in Brain Damaged Patients," (Project No. 379),
Veteran's Administration Hospital, Topeka, Kansas.
research of the effects of Cylert vroiAld be worthwhile. .
Statement of the Problem
Thus, t?io purpose of the present study is to test
experimentally the effects of magnesium pemoline in central
nervous system disordered patients on the expressive verbal
aspects of speech. In light of this discussion, then, the
primary questions to be considered in this study are:
1. Will magnesium pemoline significantly
enhance verbal expressive speech in central - -
nervous system disordered patients as meas- • 4"
ured by selected verbal tasks? , ,. ^, •
2. V/ill magnesium pemoline be significant in
the rehabilitation therapy of central nerv-
ous system disordered patients?
Importance of the Study
There is an increasing need for rehabilitation of
people who suffer from a central nervous system disorders.
One of the most frequent central nervous system disorders
is the cerebral vascudar accident. In the United States,
the cerebral vascular accident, or stroke, is considered
one of the major diseases of America. Quite often the per-
son who has suffered a cerebral vascular accident is middle
aged and has many productive years remaining, if he can bo
rehabilitated. A needless loss of manpower is caused by
speech disorders, V/ith more intensive rehabilitation pro-
grams, many of these people perhaps could return to their
previous normal patterns of life.
8As a resiilt of the Viet Nam Conflict, there have been
many young men who have received severe head injuries causing
some type of dysphasia. The importance of rehabilitating
these young men cannot be underestimated. These individuals,
without rehabilitation, would probably spend the rest of
their lives being cared for in institutions, .
Furthermore, automobile accidents have also accounted
for axi increasing number of people who suffer from severe
head injuries or other types of central nervous system dis-
orders. These accidents are happening everyday throughout
the United States, and are effecting hundreds of individuals
of all ages. These people, probably functioning as normal
p>roductive individuals before the car accident, should not
be left to spend the rest of their lives in a disabled state.
A rehabilitation program is definitely required.
Summary o f Chapter
The present chapter has attempted to elaborate on the
background of the problem under consideration, state the
questions for experimental inquiry, and establish the need
for the present investigation.
To recapitulate, speech, a very complex process, de-
pends upon the proper functioning of the central nervous
system. Only when the central nervous system functions
properly, can man produce meaningful speech. Recently, a
chemical compound raagnesiiim pemoline, has been introduced
9as a central nervous system stimulant. Researchers are in-
terested in the effects that this drug has on speech. These
investigators feel that the administration of magnesium
pemoline will be of significance in the rehabilitation of
central nervous system disorder patients.
The present study v;as designed to explore the effects
of this agent on expressive verbal behavior in central nerv-
ous system disordered persons. The increasing number of
persons afflicted with such disorders would appear to make
any such investigation worthv/hile.
CHAPTER II .
REVIEW OP THE LITERATURE
The ability to produce meaningful speech is dependent
in part upon the association areas of the brain. Through
these areas, the stimuli which enter the brain are inter-
related. There are three main neural pathways that are di-
rectly concerned with speech production: the pyramidal, the
extrapyramidal, and the cerebellar motor pathway. These
pathvjays contain billions of neurons. Each neuron has hun-
dreds or thousands of tiny dendrites receiving contact fi'om
one or many other neurons. Within each neuron are units of
free floating RNA molecules x^fhich have information process-
ing functions. With the administration of certain drugs,
the RNA synthesis is enhanced. A hypothetical relationship
between increased RNA synthesis and learning and memory
abilities has been postulated. Many investigators have at-
tempted to establish a functional relationship betvjeen nu-
cleic acid or protein metabolism to various aspects of brain
Amotions. The reports have suggested that changes in the
RNA and DNA content of the brain may be directly related to
processes of learning and memory. If, indeed, learning and
memory are enhanced by increased RNA synthesis caused by the
administration of certain drugs, then this would seem likely
to aid the patient who has a central nervous system disorder
in his relearning and rememorizing of visual ciaes, speech.
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and language. Thus, the development of an agent which stim-
ulates synthesis of brain macleic acid and enhances learning
would further strengthen the hypothesis that nucleic acids
function as the informational engram in the brain. Also,
the development of this type of an agent would provide a
valuable therapeutic aid.
Investigators have recently produced a great deal of
research concerning the effect of drugs on speech. Thie
drugs that have been found to produce the greatest effect
on speech are mainly hallucinogenic drugs, stimulants, more
specifically, central nervous system stimulants, and magne-
sium pemoline. Selected studies under each of the above
mentioned groups are reviewed in the following section.
Hallucinogenic Drugs
Honigfold used the cloze analysis to assess the
"understandability" of the spontaneous speech of a normal
subject who had received 9 rng. of psilocybin, an hallucino-
genic drug. This drug seemed to exert an enhancing effect
within the first one and one-half hours followed quickly by
a deterioration in the quality of verbal communication for
about the next tvjo hours. Cloze analysis may be thought of
as "an index of the overall correspondence or commonality
George Honigfeld "Elffect of an Hallucinogenic
Agent on Verbal Behavior," Psychological Reports
, 13 (1963),
383-385.
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between the language systera of different individuals."
Although a deceptively simple procedure to administer and
score, it has been described as having "the virtue of tap-
ping, or being sensitive to, most of the psychological de-
] 2
terminants of encoding and decoding." ' The mechanics of
the procedui'e involved the deletion of every fifth or nth
word of a presented message.
It was interesting to observe that over time, the
drug effects on language, and on other psychomotor skills,
vjere strongly reminiscent of the effects of cerebral depres-
sants, eg. alcohol. After an initial enhancing effect,
greater "understandabili ty" occurred, then a rapid deteri-
oration occurred in communication ability which lasted ap-
proximately two hours, after vjhich there occurred a rapid
return to hypothetical baseline levels.
In a follow up study, ?Iongifeld again employed the
cloze analysis to evaluate the temporal effects of LSD and
epineprine on the "understandabili ty" of verbal communica-
13tion. Ten normal male subjects recorded spontaneous
speech samples before, and at the eight fixed intervals
after injection of each of the drugs. The order of drug
''^Ibid., 383.
•"-^Ibid., 38[^. .
•"^eorge Honigfeld, "Temporal Effects of LSD-25 and
Epineprine on Verbal Behavior," Journal of Abnormal Psy-
chology
.
70 (1965), 303-306.
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administration was varied randomly. Typescripts of these
speech samples with every fifth word deleted were completed
by 13 normal adults and scored according to the number of
agreements with the original sources. The two drugs acted
differentially and the expected interaction of drug and time
effects was obtained. Compared with pre--drug level, LSD
impaired "understandability ." Peak effects for both drugs
were noted about tv;o hours after injection.
It is generally agreed that the identification proc-
esses are disturbed in the schizophrenic state. Abramson
and his associates v/ere interested in the stablemate concept
of therapy as affected by LSD in schizophrenia. '' The frames
of reference used by the nonpsychotic individual during the
adaption process in daily living were replaced to a certain
extent in the schizophrenic individiial by internalized sym-
bolic versions of the poignant personalized parts of tlie
schizophrenic's environment. It appeared to the authors of
this article, that a study of certain types of group proc-
esses might provide a better understanding of the nature of
the distorted identification process, and improve techniques
for communication with schizophrenic pat.icnts, thereby devel-
oping better methods of therapy. Although, group methods
^^H. A. Abramson, M. P. Hewitt, H. Lennard, ]rJ . J.
Turner, J. O'Neil, and S. Merlis, "The Stablemate Concept
of Therapy as Affected by LSD in Schizophrenia," Journal
of Psychology, k^ (1956), 75-81-1.
previously had been employed vji th the relatives of schiz-
ophrenic patients or with other psychotic patients, the
present investigation was designed to avoid the conflict
situation. The stabletnate therapy placed a normal individual
in the therapy situation with the schizophrenic.
The stablemate therapy concept investigation was con-
ducted in the speciaD- section of the Research Division of
ttie State Hospital at Central Islip, Nov; York. A tape re-
corder, with its microphone concealed in a small radio cab-
inet, was in an adjoining room which was equiipped with a one-
way screen. Three elements were used to structure the inter-
view: (1) the patient vj-as given either a placebo or LSD-25
dissolved in water, (2) the questionnaire previously used to
study LSD in non-psychotics was administered, and, (3)
selected pictures of the Thematic Apperception Test v;ere
discussed.
In general, there v;as more behavior change under LSD
for schizophrenic patients than for normal subjects. Comm\i-
nication between patient and stablemate dui'ing LSD sessions
was characterized by a greater amount of other oriented ref-
erences than during placebo sessions.
Lennard and his co-vjorkers investigated some of the
15
group patterns of communication under LSD-25. These three
conditions v;ere identified:
Condition I A typed script from a tape
recordinc of a group of normal
women under the influence of
LSD-25 discussing the topic,
"The Place of Women in Society."
Condition II A typed script from a tape
recording of a group of normal
women X'^ith a placebo discussing
the topic, "The Place of Women
in Society."
Condition III A typed script from a tape
recording of the members in-
dividually under the influence
of LSD-25 discussing the topic,
.-
'
"The Place of Women in Society."
In general, these statements could be made from the
results of the study. Verbal output on the part of group
members under LSD was restricted and shortened. In groups
whore some members received LSD and others the placebo,
those who had not received the drug tended to increase their
communication output. V/hen all vjore on LSD there was a
marked rediiction in negative interpersonal responses.
Despite the relatively high dosage of LSD-25 administered,
the ratio beti-^een amounts of task activity and socio-emo-
tional activity did not differ for the groups under LSD--25
and when under the normal condition. The ratio of questions
^H. Lennard, M. E. Jarvik, and H. A. Abramson,
"Lysergic Acid Diethylamide (LSD-25) A Preliminary State-
ment of Its Effects Upon Interpersonal Communication,"
Journal of Psychology . 1|1 (19'^6), 18^-198.
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to answers, as well as the ratio of orientation to evalua-
tive responses, was higher in the p;roup under condition LSD-
?S than under condition normal. The authors interpreted
this as an attempt on the part of the group to restore cog-
nitive clarity, despite the felt impairment.
Stimulant Drugs
The stimulant drugs have also received a great deal
of interest. These researchers are mainly interested in the
effect of the stimulant drugs on the individual's vei'bal
output and behavioral patterns. The following section vjill
disciass some of the more recent literature in this area.
Tourlentes and Hunsecker investigated the efficacy of
chlorpromazine in facilitating communication processes.
Thirty-four schizophrenic patients vrcre divided into three
groups. Two groups received 200 mg. of the drug and placebo
during alternate six week periods, while the third group v/as
a continuous control on the placebo. The groups \^evG roughly
equivalent for age, hospital duration, and intelligence.
The drug and placebo tablets viere coded by the manufacturer,
and subjects were assigned at random to groups by a v/ard
physician, so that the investigator and all v/ard personnel
who worked with them were unaware of the drug groups. The
T. T. Tourlentes and A. L. Hunsecker, "Chlorpro-
mazine and Communication Process," Archives of Neurology
and Psychiatry. 79 (19.^), it.68"i^72.
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groups not on the drug at a particular period, as well as
the controls, received a placebo tablet identical with the
drug. Initially and at two subsequent six week intervals,
various psychological tests, recorded psychiatric interviews,
socioraetric evaluation, and cinematographic sampling of
spontaneous behavior in a relatively unstructured situation
wore undertaken for each subject. Results foiled to estab-
lish that 200 mg. of chlorpromazine as prescribed, signif-
icantly altered communication process as measured in this
study. Some evidence, however, supported the observation
that there was a reduction in anxiety with this drug.
P'inl: investigated the effect of an antlcholenergic
agent, dlethazlne, on the EEG , behavior, and language pat-
terns on )-|.0 psychiatric patients at various stages in the
17
course of electroconvulsive treatment.' Alterations in
EEG wore concurrent with behavioral changes. In patients
with delta activity, the time and voltage of delta activity
decreased. The patients behavior showed increased rest-
lessness and agitation, visual Illusory sensation, and delu-
sional thoughts about their illness. Syntactic patterns
described for convulsive therapy were observed. Use of
third person, qualification, and displacement decreased.
In dyadic analysis there was a decrease in the coefficient
M. Fink, "Effect of Antlcholenergic, Dlethazlne on
EEG and Behavior " A'rchieves of Neurolo gy and Psychiatry ,
80 (19^p0), 380-387. -
18
of variation. These observations vjcre discussed in the
framework of the neurophysiologic adaptive hypothesis of the
action of convulsive therapy anid it was concluded that the
biochemical basis for convulsive therapy was similar to that
of cranio-cerebral trauma. Changes in acelylocholine cho-
linesterase metabolism are inimately related to the behav-
ioral effect and the EEG desynchronization may be a physio-
logic concomitant of hallucinogenic activity.
The purpose of a study by Gottschalk and his col-
leagues was to test the efficacy of a method of assessing
the subject and behavioral effects of psychoactive drugs in
the hu.man subject. The method involved the psycholin-
guistic analysis of short samples of the subject's speech.
Twenty dermatologic subjects at the Cincinnati General Hos-
pital participated in a double-blind, placebo-crossover
study in which the psychoactive drug administered was per-
phenazine. Five minute samples of their speech v/ere e].icited
with standard instructions and recorded on tape at approx-
imately the same tirae of day on five successive days. Anal-
ysis of the verbal sample shox\fed a reduction of the median
scores for 16 out of 20 patients in an index of "hostility
directed outward," a scale which includes in its scoring
* L. A. Gottschalk, A. Gleser, C. Goldine, K.
Springer, S. M. Kaplan, J. Shannon, and W. 0. Ross, "Effects
of Perphenazine on Verbal Behavior Patterns," Archieves of
General Psychiatry. 2 (i960), 632-639.
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not only hostile, destructive references overtly originating
from the speaker, but also displaced, projected, and denied
references of this kind. Three of the patients, whose hos-
tility scores increased while taking perphenazine, had scores
below the median for this series of subjects while on the
placebo. Furthermore, there was suggestive evidence that
these four subjects had distinctive personality features
other than those of subjects whose hostili ty-directed-outward
scores decreased with perphenazine. This psychoactive drug
had no notable effect on the hostility-directed-inward scores
of the patients as a vjhole. Those patients, vjhen on the
placebo, who had free anxiety scores in the upper one- third
range of the group, tended to shovj no consistent direction
of change with perpVienazine . Five of the six patients over
65 showed an increase of the free anxiety score while on
perphenazine. Verbal content analysis revealed that there
was a significant trend for dermatologic patients while on
perphenazine, to make more references to feeling of personal
bodily and emotional well-being. Also, with perphenazine
the patients tended to use a greater number of v/ords ex-
pressing positive, approving feelings such as "good," and
"happy." The authors felt that this method of measuring
the effects of psychoactive drugs by verbal content anal-
ysis could prove to be a useful therapeutic method for
patients who have personality disorders.
The purpose of an experiment reported by Goldman,
20
Skarbek, and Henderson was to study the' effect of chlor-
proma^.ine on such cognitive functions that have been shovm
by the investigator to be measurable in terras of verbal be-
havior. These v;ere hesitation pauses in spontaneous
speech vjhich in previous work had been shown to reflect
processes concerned with the selection of words and the
formulation of meaning. The experiments consisted in evok-
ing spontaneous utterances of speech at two levels of cog-
nitive complexity involving descriptive and general state-
ments in normal and highly intelligent adults. Speech of
this kind had been studied before and the two levels were
shown to diffei^ vrldely in pause duration. In this investi-
gation such speech v;as studied .in conditions of no drug,
sodium amytal, and chlorpromazine . The advantage of pause
time in speech, as a measure of cognitive changes under
these conditions, is that it makes possible a separation of
the behavior accompanying the processes concerned with
achieving cognitive results from the quality of the results
themselves. This enables the researchers to gain a picture
of the drug action in relation to the mechanism involved in
cognitive activity apart from what it achieves. The latter
was assessed independently from judges rating of the cog-
nitive quality of the statements made, with the level of
^F. Goldraan-Eislor, A. Skarbek, and A. Henderson,
"The Effect of Chlorpromazine on Speech Behavior," Psycho -
pharmacologia
. 7 (1965), 220-229.
21
generalization being the criterion. Thus, the drug effects
could be studied separately for cognitive labor and for its
efficiency in terms of cognitive achievement.
The results shov/ed the effect of chlorpromazine on
pause time, in contrast to sodium amytal, to be selective,
varying in direction v;ith individ\ials . The effect on the
cognitive quality of the linguistic product was shown to be
linked to the effect of ch] orpromazine on pause behavior,
\-jlth the pause time appearing under chl orpromazine as under
normal conditions, to be involved in p;cnerating complex
verbal structures. Under sodium amytal, on the other hand,
no such link between hesitation and information was found.
Central Nervous System Stimulants
Researchers interested in patients vjho demonstrated
a central nervous system disorder, began experimenting vjith
the effects of increased DHA and RNA in these individuals.
By 193^5 ^^ ^^'^ been shovm that the amount of nucleic acid
decreased with age. This foot was interpreted by the re-
searchers as a possible connection betijecn increased DNA or
RNA as a hypothetical relDtionshlp to memory.
The effect of the administration of ribonucleic acid
upon memory defect in the aged ?iad been studied at the Allan
Memorial Institute since 196|5 . These studies v;ere initiated
by a report made by VJeiss, who, in summarizing his work about
the neuron, pointed out that this structure is constantly
22
renewing Itself; that the material necessary for its con-
tinued activity is produced at the nucleated end and passed
20toward the end plates. He referred to the finding of
Hyden, vjho induced a high rate of protein synthesis in the
cell from the elevated nucleic acid concentration in and
around the nucleus, and to the findings of Samuels that
labelled phosphoprotein seemed to shift peripherally in
21 22
nerves. ' Katz and Halstead had also proposed that,
"neurons involved in memory become fully functional only
after chemical striactural changes" and had suggested that a
neuron became operative in this regard through the formation
of a ncvj protein molecule. -^ They assumed that this molecule
was a nucleoprotein acting as a template for the synthesis
of protein re})licas.
Hyden seems to have been the first to advance the
hypothesis that the substrate of memory is ribonucleic
^'^P. Weiss, "The Life History of tVie Neuron," Paper
presented at the annual meeting of ARKMU (195^).
H. Hyden, "Spectroscopic Studies on Kcrve Cells in
Development, Grovith, and Function," Genetic Neurology
(University of Chicago Press, 1950), pp. 177--193.
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A. J. Samuels, "Distribution, Exchange and Migra-
tion of Phosphate Compounds in the Nervous System, " Amerlcai
Journal of Physiology. l6I| (19^1), l~l5.
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J. Katz and W. S. Halstead, "Protein Organization
tal Function," Comparat ive Psycl-iology Monographs
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1-11.
and Ment?
(1950), 33
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acid. He pointed out that the many cbriibinations permitted
by the rearrangement of its four bases provide a substance
which in theory could encode 10 or more bits of informa-
tion.
Sved demonstrated that the blood ribonuclease level
was significantly correlated with increased age, but he found
no significant correlation between the blood ribonuclease
level in aged Individuals with memory deficit and those wlth-
out. After preliminary work on animals, Cameron, Sved, and
Wainrib began in 19!?6 to study the effects of intravenous DNA
and later RNA in the human subject. ^ It proved very diffi-
cult to get these substances into a satisfactory solution
and, after approximately a one year trial, intravenous admin-
istration was abandoned in favor of oral RNA until 1961, when
a satisfactory intravenous solution was achieved by a bio-
chemical team under the leadership of Sved.
Cameron, Sved, Soloym, and Wainrib stated that no
matter hovj ribonucleic acid was administered, little change
H. Hyden, "Nucleic Acids and Pr'otejns," In Neuro -
chemlstry (Charles C, Thomas Publisher, 19^5).
-^S. Sved and D. E. Cameron, "Ribonucleic Acid and
Psychiatric Therapy," Current Psychiatri c Therapies
, \\.
(196)4), 127-133.
D. E. Cameron, S. Sved, and B. V/ainrib, "Effects
of Intraveneous Administration of Ribonucleic Acid Upon
Failure of Memory for Recent Events in Presenile and Aged
Individuals," Rec ent AdvanceSs in Biological Psychiatry
(Plemun Press, Y^T^'T) . "v.-
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of an omeliorative ns.ture could be brought about in the
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mnemonic function if the memory deficit was severe. The
authors vjorked predominantly with three categories of pa-
tients: those suffering from presenile psychosis (primarily
Pick's and Alzheimer's diseases), from senile psychosis, and
from arteriosclerotic brain syndromes. A limited number of
patients suffering from alcoholic Korsakoff psychosis also
have been given ribonucleic acid. All patients under treat-
ment were placed on two grams of RNA which was administered
orally. The patients were, in addition, given intravenous
RKA, past experience having shovm this method to be consid-
erably superior to the first type of oral administration.
The amount of I?NA given intravenously varied from two to ten
grams depending upon the reaction of the patient; the fre-
quency of administration varied from daily to once or twice
per vreek. When ten grams were given, it was diluted in
1,000 cc ' s of 5 per cent glucose and normal saline and given
usually over a five to six hour period. The patient was
premedicated one-half hour before with atropine demoral mag-
nesium. In some cases, the RNA administration' was accom-
panied by intravenous ATP without, hovjever, noticeable' gain.
For the assessment of mnemonic function, the authors
^^D. E. Cameron, S. Sved, L. Solyom, B. V/ainrib and
H. Barik, "Effects of Ribonucleic Acid on Memory Defect,"
American Journal of Psychiatry, 120 (19 63), 320.
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employed the use of these four measures':
1. The V/eschsler Memory Scale
2. A counting test
3. Six parameters of a conditioned reflex procedure
]\, Tests based on the capacity for- time estimation.
The EEG vjas used as one means of following the effects of
ribonucleic acid.
Favorable changes were recorded in all three catego-
ries of mild organic deficit; brain arteriosclerotic, senile
dementia, and presenile dementia. The resxilts, however,
were limited in moderate cases of organic involvement and
were negligible in far advanced cases. Unfortunately, when
one dealt with an organic brain syndrome, memory disturbance
was only one of the deficits. If progression could be
halted, or if reversal xifas brought aboiat in the memory def-
icits, this did not necessarily affect the progression of
the organic process as a v/hole. Plence in patients in vjhom
favorable effects had been achieved with resj^ect to mnemonic
fianctioning, there couid be, nonetheless, a continuing pro-
gression of defect in judgement, in the maintenance of so-
cially acceptable behavior, and in motor and sensory func-
tions.
Nevertheless, this procedure constituted the only
method which has produced a halting and, in favorable cases,
a reversal of deterioration in memorial function in organic
brain syndromes. The procedure v/as, hovrevor, in the
26
experimental stages and inforraation was being sought as to
whether the effects were produced by the ribonucleic acid
as a vjhole or whether some component thereof could be iso-
lated vjhich might have a still higher level of efficiency
of operation. There v;ere no leads as to how ribonucleic
acid administered orally and intravenously produced this
effect.
In a more recent series of experiments, RNA was ad-
ministered to the patients, as earlier experimentation had
proved it to b e supoi'ior to DNA. After prolonged investiga-
tion, Cameron and So] yom found that the oral administration
of a slowly dissolving tablet eliminated the occasional
28
shocklike effect of intraverioTis treatment. Also, the
slowly dissolving pjll was better than oral fluid adminis-
tration because t?ie latter sometimes produced abdominal dis-
comfort, cramps, and diarrhea.
The total number of subjects involved in Cameron's
experiments was 8I[
.
"^ These patients vjere divided into
groups one and two. The first group consisted of l\.l aged
individuals vjho v/ere then attending the Allan Memorial
Institute of Psychiatry. In this selection, the authors
excluded those who suffered from mood changes, recent
^°D. E. Cameron and L. Solyom, "Effects of Ribo-
nucleic Acid on Memory," Geriatrics, I6 (I96I), 7l(..
^^Ibid.. p. 7lf-8l. , .. • •
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cerebral accident, and/or undernourishment. The second
group of patients i-jere chosen from a geriatric ward of a
provincial mental hospital. Their illnesses v/ere much fur-
ther advanced than those in group one. The second group v;as
also divided into two subgroups, A and B. The first sub-
group was given a placebo preparation, while the latter re-
ceived RNA on a double-blind basis.
Assessment in group one vjas based on the VJechsler
Memory Scale, a counting test, and information supplied by
the patient and by his relatives. RNA was administered
orally to the majority of patients in the form of a special,
slo^^^ly dissolving pill, in dosages ranging from 2 to 75 grams
daily. In llj cases, hovjever, daily intravenous injection of
5)0 to 2,000 mg. of RNA in a 10 per cent solution was admin-
istered. V/i th group tv/o, a conditional reflex test was added
to the Wechsler Memory Scale and counting tests assessments
before commencemeiit of the drug and placebo experiments.
Three months later, reassessment by the same method vras re-
peated. All conditioning was carried out by the same psy-
chiatrist and all testing by the same psychologist. The
pattern of ribonucleic acid administration was three grams
daily during the first week, six grams daily during the
second vjeek, and nine grams daily from the third to twelfth
weeks. Al], medication was given orally and the placebo was
administered in the sirailiar manner.
The administration of RNA had a favorable general-
28
effect upon rtieraory retention failure in the aged. The ear-
lier in the progress of the condition RNA was given, the.
more favorable the effects. Patients vjith moderately ad-
vanced memory failure did better on RNA than did patients
with marked memory impairment. If the retention span was
below ){.0 seconds according to the counting test, the result
was apt to be either a slight improvement or a slowing down
of the rate of progression of rotentjon failure. Above )|0
seconds, the higher the initial score, the more marked the
improvement was apt to be. The dosage of RNA was highly
individual to pace with the advancing aging process. In
both experimental groups, arteriosclerotic patients re-
sponded more favorably to RNA than d :i d senile dementia
patients. In ten cases, suspension of treatment resulted
in a further decline of memory, which was halted by reins ti-
tution of RNA. RNA was given either in the form of a slowly
dissolving tablet or intravenously. Intravenous administra-
tion was apt to be accompanied by disturbing side effects.
Of the methods of assessment used, the counting test and the
conditioned reflex test were most closely corre]ated. Among
the favorable changes in addition to those affecting the
memory, were increased alertness, interest, initiative, and
confidence
.
Magnesium Pemoline
Prom the results of the research done vjith RNA and
29
DNA, North Chicago Abbott Laboratories developed the. compound
magnesium pemoline under the trade name, Cylert. Cylert Is
a combination of 2-lmlno-5-phenyl-J|-oxaz,olldinone and mag-
30
nesium hydroxide. The developers of magnesium pemoline
felt that this compound coiild stimulate the production of
the brain's RNA, thus improve learning and memory.
Simon studied the effect of magnesium pemoline on the
systems in the brain that are responsible for both FiNA and
protein synthesis in vivo and viti^o. By using C ' '' ortic
acid, it v;as demonstrated t?iat magnesium pemoline vjas cap-
able of enhancing the quantity and specific activity of
brain nuclear RNA in vivo. The inhibition of protein syn-
thesizing system of the brain which was also observed,
failed to be significant. Simon used the vivo test system
to determine the effect of magnesium pemoline on the RNA
synthesis of the rat brain. Male Sprague-Davjley rats were
divided into two gi'oups of six animals each. The animals
were Injected with magnesium pemoline or methoclo, the
placebo. .After a 30 minute period all the animals were in-
jected Intracranlally with ortic acid-2-C-lI|_. At the end
of an additional period of 60 minutes, the rats brains VJere
^^Abbott 30L|000: Cylert, a combination of 2-imino-
5-phenyl-l|-oxazolldinone and magnesium pemoline.
^ L. Simon, "Magnesium Pemoline: Enhancement of
Brain RNA Synthesis in Vivo," Permission to cite by the
author.
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removed and prepared for analysis. Each sample was analyzed
for total RNA content by its absorption at 260 mm. and
counted for radioactivity. Magnesium pemoline did not cause
an increase in the specific activity of total brain RNA pro-
duction, however, there was an increase in total micrograms
of nuclear RNA/grara of brain tissue and an increase in the
specific activity of nuclear RNA. Simon showed, then, by
the vivo labeling technique, that magnesium pemoline in-
creased the synthesis of brain nuclear RNA and supported the
view that the main mode of action of magnesium pemoline was
to enhance the synthesis of brain nuclear RNA. In addition,
he found that magnesium pemoline had no effect on the major
system in the brain responsible for protein synthesis.
Magnesium pemoline and dextroamphetamine, two central
nervous system stimiilants, were tested to see if they im-
proved learning in human subjects. This study, by Burns and
his associates dealt directly with the effect of these stimu-
lants on the associative processes, specifically the acquisi-
tion rate in a learning task in a population that was in-
32tellectually above average. The subjects consisted of 30
male university students. A double-blind method v/as employed
and each subject was given a single oral administration of
one drug. The five drug conditions for this study were as
32
^ J. Burns, R. House, F. Penoch, and J. Miller,
"Effects of Magnesium Pemoline and Dextroamphetamine on
Human Learning," Science
.
l55 (196?), 8^9-851.
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follows:
' 1, Magnesium pemoline 2^ rag.
2. Magnesium pemoline 12.5 ^E'
3. Magnesium pemoline 6.25 wg.
l\.. Dextroamphetamine 13' rng.
5. Placebo
Two tasks were used in this experiment. The simpler one was
a reflation time task in which the correct response for each
light was to press the button directly in front of the light.
The learning task required the subject to leai'n which single
key was the correct response to each light when the keys
were randomly assigned, except thot t?ie correct button was
never immediately in front of the light associated with it.
The subjects under the placebo learned faster than the sub-
ject under any of the several doses of magnesium pemoline,
however, none of these differences reached statistical sig-
nificance. The subjects vjho received dextroamphetamine
learned significantly slovjer than those who received the
placebo or the magnesium pemoline. Also, it was found that
higher doses of magnesium pemoline in humans actually in-
hibits learning.
The purpose of an experiment by Tolland, Hagen, and
James was to determine the effect of a single dose of Cylert
on the acquisition of new information and on its recall in
patients diagnosed to be in the chronic phase of the
32
33Korsakoff Syndrome. The subjects v/ore three vjomen and one
man who alD. had a record of alcoholism and had observable
signs of Wernickes Syndrome prior to their admission to a
mental hospital . Four different experimental conditions
were employed in this study, ho;\rever, the same basic tasks
were used in all the experimental situations. The subjects
were given a single, oral dose of 50 mg. of Cylert or a
lactose placebo according to a double-blind procedure.
There were three learning tasks requii'cd. The first task
was to recall a newspaper report ^^fhich was read only once
by the experimenter and consisted of six sentences and di-
vided into 20 units. The second task was that of learning
a list of ten common monosyllabic CVC (consonant-vowel-
consonant) words. The subjects viere allowed three minutes
to memorize the vjords. The last task for remembering called
for memory of a series of eight figure dravjings of familiar
objects (eg. hammer, clock, cake, etc.) v/hich wore projected
from prepared slides.
The purpose of the first experimental condition was
to list the effect of Cylert on the acquisition of nev: in-
formation and on its recall. The second experimental con-
dition served the same purpose as the previous one except
that the dosage was decreased 2^ mg. Also, a second
33G. TaDland, D. Hagen, and M. James, "Performance
Tests of Amnesic Patients with Cylert," The Journal of Nerv -
ous and Mental Disease
.
ll\l (1966), Ji.21-Il29.
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stimulant drug was used as a control, and a fevj added tasks
were employed in order to test the drug's effect on a wider
range of functions. The third experimental condition tested
the effect of Cylert, administered regularly over a rela-
tively long period of time, on learning, memory, and some
basic functions. Any effect observed was compared with
changes attributable to a single dose, as well as with per-
formance on a prolonged placebo treatment. The fourth ex-
perimental condition tested the effect of Cylert, given in
daily doses of 30 I'ig. for a period of three weeks, on per-
formances in tasks of learning, memory, and other related
functions.
In a follow up study by Talland to his first investi-
gation, tvjenty-four stxidont volunteers, between ages 21 and
2^ years, served as subjects on three or four occasions at
"31
weekly intervals for periods of about three hours. ^ At the
beginning of the experimental sessions, the subjects were
administered a tablet of 25 ^g. of Cylert or a lactose
placebo, and then were r^iven a rest period of 70 minutes
which they spent reading. In the first session, the rest
period lasted for 90 minutes, but in subsequent sessions,
tVie time betvjeen 70 and 90 minutes was occupied by tests of
delayed recall of a narrative text and of a maze learned the
^^G. Talland, "Tests of Learning and Memory with
Cylert," Psychopharmacologia
. 10 (I967), kk^-k^l
.
.3k
previoiis week. The time betv/een 90 and 120 minutes was used
for learning nev; tests. Then the subject received his second
tablet, either Cylert or placebo, and five minutes later he
started a test of sustained attention. This testing lasted
50 minutes and was foD.lowed by tests of recall and relearn-
ing. The drugs were administered by the double-blind pro-
cedure.
These experiments demonstrated that Cylert was cap-
able of improving performance by human operators, though
possibly only by mitigating fatigue effects. Talland's ex-
periments reported the favorable drug effect was fairly
instantaneous and manifest in an increase of correct re-
sponses to a class of visual patterns that were specified
as signals, without an increase in false positive responses.
The gain in performance attributable to the drug was, there-
fore, not achieved by lov;ering the criteria for responses
but by the processes affected, namely those involving per-
ception, short-term retention, and matching of data.
In summary of Tolland's studio? Cylert administered
in single doses of 23' mg. improved accuracy in performance
of a continuous attention task. This effect was strongest
wibhin an hour from oral administrsti on of the drug, and on
a task that involved a relatively difficult test in short
term memory. These findings were considered as evidence
for a non-specific alerting or anti-fatigue effect, as dis-
tinct from a specific effect on memory function attributed
3^
to Cylert.
A survey of these experimental findinf^s gave little,
if any, confirmation of Cylert as a treatment of patholog-
ical memory disturbance. The few results that could sug-
gest some benefit from this drug arc offset by others that
show improved performance with the placebo. Although the
experimental procedures employed may not have probed al].
the functions impaired, they v/ero sufficiently diverse and
representative of those impaired functions to allow for a
wide generalization of the negative results obtained. Clin-
ical observations made by the experimenters and the ward
personnel also failed to give significant reports of im-
provement of other changes in the patients behavior as a
result of the experimental drug treatment. By the same
token, there was no evidence of any side effect with the
improved oral administration procedure, nor did the patients
complain of discomfort or unusual sensations. Althougli there
were some instances of improved performance with Cylert, none
of the experiments furnished evidence that this effect is
reliable under the conditions of the double-blind design
which also controls for the practice elc;nent . Neitlier did
the researchers indicate that Cylert exerted an adverse
effect on performance. Therefore, v;hatever inf]\ience this
drug may have on brain metabolism, it is unlikely to offer
a pharmacological remedy for severe memory disorders.
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Chapte r Summary
This chapter was concerned v;lth reviev/ing the lit-
erature concerning the effect of drugs on speech. The areas
of drug research reviev;ed x^rere hallu.cinogenic drugs, stimu-
lant drugs, and central nervous system stimulant drugs. Of
specific interest in the central nervous system stimulant
drug area, v/as the effect of the chemical compound magnesium
pemoline. This nev7 drug, recently developed by Abbott
Chicago Laboratories, created a great deal of interest for
researchers who were concerned with the rehabilitative pos-
sibilities of Cylort. This chapter suggested the potential
fruitfulness of investigation in the area of drug research
and to the further understanding both of specific drug
effects and of the speech processes.
CHAPTER III
PROCEDURE
Sub.i'ects
Six adult patients of the neurolof^y service at the -
Veteran's Administration Hospital v/ho exhibited some speech
difficulty associated vjith a history of nervous system dam-
age or injury v/ere selected for this study. The subjects
displayed different types of speech difficulty with varying
degrees of severity. Patients taking certain anticonvulsents
,
psychotropic, or central nervous system stimulant drugs were
excluded from the study. The patients v/ere sufficiently in-
tact psychologically and physically to be testable with
speech tests such as the Halst ead-Wepman Screening Tests for
Aphiasia, the Sklar Aphasia Scale, the Missouri Developmental
Test for Articulation, the V/est, Kennedy, and Carr Sentences
Survey, or by any standard language testing technique neces-
sary for speech evaltistion.
The patients had to be capable of giving their con-
sent to participate in the experiment and signing Veteran
Administration Form 10-3203, Consent for Use of Pic tur e and
Voice
. Authorization was also secured from the ward physi-
cian and Service Chief.
Experimental Design , ' /
For the piirpose of controlling order effects and
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examiner bias, a double-blind procedure was utilized. The
testinjT; of each subject took approximately one-half hour per.
test run. However, if the subject was unable to work or per-
form for this length of time, then tvjo, fifteen minute peri-
ods V7ere employed. During the course of t?ie experiment, each
siabject was tested five times. The subjects were assigned
randomly to magnesium pemoline schedules or placebo schedules,
The assignment of the subjects to magnesium pemoline sched-
ules or placebo schedules was unknovm to the test adminis-
trator.
During the magnesium pemoline schedule, each subject
was administered the American measure of 50 milligrams of
magnesium pemoline in tablet form each day. This dosage
continued over a two week period. Since the Federal Drug
Administration monitors all ne\-j drugs, the physical condi-
tions of the subjects were carefully noted while receiving
the experimental drug. All subjects signed an agreement in
the presence of a witness that they understood that they
were being given an investigational drug. The placebo was
administered in a manner identical to the administration of
the magnesium pemoline.
Before and after each pharmaceutical treatment, base-
line tests vjere performed. Thus, five experimental condi-
tions v/ere established; two pharmaceutical, magnesium
pemoline and placebo, and three baseline, no treatment. The
entire group of subjects x-Jas pre-tested (Experimental
•. . 39
Condition I) and then administered either the placebo or
magnesium pemoline for a tv/o vjoek period. During this
period, all subjects were tested again (Experimental Condi-
tion II). After the tvjo week period of placebo or magnesium
pemoline administration, a vjook of no medication was allo^^red.
This v;oek between each of the pharmaceutical conditions was
employed in order to minimize the effects of any residuals.
At the end of this period, all subjects were retested (Ex-
perimental Condition III). Again, after this testing, the
subjects were placed on magnesium pemoline schedules or
placebo schedules. The new schedule was the opposite of the
schedule that the subject was assigned for the preceding
period. For exampHo, if the subject had been administered
magnesium pemoline for the first pharmaceutical condition,
then he v/as given the placebo schedule for the second phar-
maceutical period. However, if the subject had been given
the placebo schedule first, he then would be given the mag-
nesium pemoline schedule for the second pharmaceutical
period. After the new schedules had begun, the subjects
were tested again (Experimental Condition IV) . When the
final pharmaceutical period was complete and the subjects
were no longer receiving any medicatio?i, drug or p].aoebo,
they were post-tested for the final baseline data (Experi-
mental Condition V)
.
The same tests and testing order were utilized for
all s\:.bjects in all experimental conditions.
^0
In that changes resulting frora rnedioatlon are not
always directly ascertainable from particular tests and be-
come more obvious under conditions of observation of the
person's behavior, the use of a systematic procedure for
ward observation of experimental patients by nurses and
nursing assistants was also utili/.od. Th^i s procedure vjas
similarly carried out with the double-blind method. The
nurses and nursing assistants reported their observations
on particular patients to the ward physician upon request.
The nurses and nursing assistants informally expressed what
they had observed in the patient's general behavior or any
noticeable change that had occurred.
Test Events
Each subject was administered the follovjing battery
of tests.
1. Sklar Identification of Objects Test"^
2. Schuell Object Naming Test^
3. Recall Test
k. Oral Reading Test^'''
35Maurice Sklar, Sklaj" Aphasia Scale (Western Psy-
chological Services, Beverly Hills, California, 1966).
^^"riildred Schuell, The Minnesota Test for Differen -
tial Diagnosi s of Aphasia (Research Edition, form 7 )
.
-^'Velma Avant and Charles Hutton, "Passage for Speech
Screening in Upper Elementary Grades," Journal of Speech
and Hearing Research'
.
XXVII (February 27, l^Z) ,'~li0^4E
.
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5. Vocal Encoding Test"^ .
Each subject served as his ovm control for each test.
The some patient was tested approximately at the same time
of day under the five experimental conditions in order to
reduce intra-- individual variability related to fatigue.
Sklar Identific ation of Obj ects Test. The Sklar
Aphasia Scale was developed by Maurice Sl:lar in i9l|-8 to pro-
vide objective measurements and evaluations of speech and
39language disturbances resulting from brain damage. The
items in the subtest, Sklar Identification of Objects Test,
measure auditory verbal comprehension as sampled by verbal
stimuli requiring only gestural or motor responses that in-
dicate recognition and comprehension. In the present inves-
tigation the examiner spread twenty common objects before
the patient and then asked, "Do you sec all these objects?
I'm going to name them. 1 want you to point to the object
or pick it up, after I say that object's name. Wait until
I tell you the object's name, then show me. Are you ready?"
The examiner stated one object's name at a time, "Shov; me
the comb." The examiner allovjed the subject to complete his
response before he proceeded to the next object. If the
subject did not respond to the first request, then the
-^ James J. McCarthy and Samuel A. Kirk, Illinois Tes t
of Ps ychol inguistic Abilities (University of Illinois,
Urbana, Illinois, 19'5l).
^^Sklar, ££. cit . , p. 1.
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sentence v/as repeated again, "Shoi-J rae the comb." If, hov;-
evor, the subject still did not respond, the examiner pro-
ceeded to the next object, "Show me the pencil," counting
the previous request as an error. Or, if the subject, after
the first statement, "Show me the comb," pointed to an in-
correct object, then the statement, "Shovj me the comb," was
repeated. If the subject still pointed to sn incorrect
object, then the examiner proceeded to the next object,
counting the previous response as an eri'or. But, if the
subject pointed to the correct object on the second request,
the examiner asked for the third time, "Show me the comb,"
If he was correct the third time, his response was coimted
as correct, but if he was incorrect the third time, his
response was counted as an error. The time taken for the
completion of the task was also recorded.
Schuell Object Naminp; Test. The Schucll Test for
Aphasia was developed by Hi Idred Schuell for adults whose
language abilities became impaired after normal language
functioning had been established. The test is directed
primarily toward obtaining essential information which could
be useful for the rehabilitation of aphasic persons. A sub-
test, the object naming test, examines the higher symbolic
levels of expressive ability of the subject tVu-'ough word
finding or picture naming methods.
^ Schuell, o£. cit
. ,
p. 1.
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The Schuell Object Naming Test, as used in the pres-
ent study, required the subject to name the picture that was
presented on a televievjer. The slides vjere simple, black
and white pictiires of common objects. A total of twenty
slides was presented to the subject. The examiner said to
the suVjject, "You vjill see a picture on the screen." (exam-
iner pointed to the screen) "I want you to tell me the name
of the picture." The first picture was tticn presented on
the screen for the subject. The examiner presented the
slides one at a time and allowed the subject to complete his
response before proceeding to the next slide. If the sub-
ject mislabelled the picture, that item v/as scored as in-
correct, and the next picture was presersted. If no response
was made, twenty seconds were allowed before presenting the
next picture. The number of correct pictures identified was
the total score. Also, the elasped time necessary for the
test completion was recorded.
Recall Test
.
The recnll test was concerned specif-
ically with the central nervous system disordered patients'
ability to recall certain words. The examiner asked the
subject, "Tell me as many words as you can think of begin-
ning with the letter Mi'." The subject was allowed tv/o min-
utes for this task. Once the test had begun, the examiner
made no further statements until the test time period was
completed. At the end of the test, the total number of
words was counted. Repeated words v;erc counted only once.
The score vjas recorded as the total number of "h" words
recalled.
Oral R eading; T est. The oral reading test developed
by Avant and Hutton provided a measure of the subject's
articulation in connected speech and for an evaluation of
other factors such as rate, voice quality, voice pitch,
loudness, and breathing. Words for the passage vjere
selected from the vocabulary of the Row, Peterson basic
primer and from the first 1,000 vjords of the Rinsland list.
The 123 word passage was presented to the subject on a card
in large print and double spaced in an effort to reduce the
influence of possible visual problems. The examiner handed
the card to the subject and said, "Read this paragraph
aloud." If the subject asked for assistance on a particular
vjord, the examiner supplied the correct word. The oral
reading test v/as scored by the length of time required to
read the j^sragraph. Original] y, the oral reading test had
been selected to give a measure of both the subject's artic-
ulation pattern and his response time. However, the artic-
ulation measure was excluded since the errors that were made
on the oral reading test vjere felt to be those of misread
words, rather than articulation errors. The misread words
would have been scored as articulation errors, which would
have presented inaccurate data.
Avant and Hutton, op. c it
.
^
p. Ij^li.
.
Vocal Encoding Test
The Vocal Encoding Test vjas a section test taken from
the Illinois Test for Psycholinguistic Ability developed by
McCarthy and Kirk In 1961.+^ The purpose of the Vocal
Encoding Test was to determine the number of unique, mean-
ingful ways in which the subject could verbally characterize
a simple object like a ball or block. Each response by the
subject had to be clearly understood by the examiner before
it was scored. If the subject's response vjas unclear, then
the examiner immediately questioned the subject about that
response to determine the subject's meaning of his answer.
The questions asked were, "V/hat do you mean?" or, "Tell me
more about that." This type of questioning did not lead
the subject to a desired response, but simply Informed him
that ?iis meaning was unclear.
One demonstration item was employed for this test.
The subject was handed a blue marble and asked, "Tell me
about this." The subject could handle the marble if ho
wished. If, hov/ever, ho did not respond with a few mean-
ingful characteristics of the marble, he was asked some
leading questions such as, "What is it? V/hat is it made of?
V/hat color is it? What do you use it for?" These questions
were used only for the demonstration item. After the sub-
ject responded to these questions, the test began immediately
McCarthy and Kirk, ££ . c_l_b., p. 1.
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The morble was placed aside, and the examiner handed the
subject a ball and said, "Tell me all about this." After
about one minute of response time, or sooner if the subject
clearly indicated that he was finished, the examiner said,
"Tell me something else." If the siabject appeared to have
exhausted his repertoire before one rain\.ite, even after the
second statement by the examiner, the next item was presented
to the subject. However, if the subject was not finished
respondin|3 in a minute, the next Item was not presented until
the examiner had said, "Tell me something else," and the sub-
ject had clearly indicated that he was finished vxith his
response. The major variable v;as the number of unique vjays
in vjhich the subject responded; since the test was open
ended, the subject could give any of an infinite number of
responses. All responses were recorded verbatim as the sub-
ject talked about the object. The subject's score was de-
termined by the total number of acceptable responses accord-
ing to the scoring procedures of the test manual. Also, the
time taken for t Kio task was recorded.
The entire testing period vjas tape recorded except
during the adm-inistration of the Sklar Object Identification
Test.
Chapter Summa ry
The present chapter has described the subjects, the
experimental design, test events, and the testing procedure
r *
•
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that were employed for the study.
The design of the investigation indicated that five
experimental conditions vjere established to study the effects
of magnesium pemoline on the speech of central nervous sys-
tem disordered patients. The Experimental Conditions 1,
111 and V were developed to invest ig;ate baseline informa-
tion and to study the effects of learning and practice. The
purpose of the pharmaceutical conditions, ICxperimenta]. Con-
ditions II and IV, was to establish and investigate the
effect of the magnesium pemoline and the effects of the
placebo on speech. When the subject was receiving the mag-
nesium pemoline, the effects of the drug would be measured
by comparing the drug condition to the baseline conditions
or to the placebo condition. Also, the placebo condition
could be compared with the magnesium pemoline condition or
with the baselJne conditions to study the effects of the
process of administrating a "medication."
m
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CHAPTB]R IV
RESULTS AND DISCUSSION
The basic purpose of this investigation was to deter-
mine the effects of raagnesium pemoline on the speech of cen-
tral nei'vous system disordered patients. The study was con-
cerned also with the rehabilitative value of magnesium
pemoline.
After completion of the testing for all experimental
conditions, it was revealed that all subjects received mag-
nesium pemoline during the first pharmaceutical condition.
That is, Experimental Condition I established baseline data,
Experimental Condition II v/as the testing during the adminis-
ti'ation of magnesium pemoline, and Experimental Condition III
set baseline test results after the magnesium pemoline admin-
istration had been completed. The placebo administration
occurred during the foiirth experimental condition, and the
final baseline testing for the investigation was completed
in PJxperimental Condition V.
Because of the small number of subjects employed in
this pilot study, the preliminary results of this investiga-
tion with the experimental drug seem best illustrated by the
follovring case reports.
Sub j e c t s
Case I
.
Case T was a 60 year old veteran who suffered
^1-9
a cerebral vascular accident approxiraately a year and a half
ar,o. On the Sklar Object Identification Test, he maintained
the maximum score possible under the five experimental con-
ditions, hovjever, the time taken to complete the task dis-
played some variability. During the magnesium pemoline
testing and the fifth experimental condition testing, Case
I required a shorter time period than in the remaining ex-
perimental conditions. The time decrease during the drug
administration possibly may be explained by the effect of
Cylert; the decrease in time during the fifth experimental
condition could have been a function of practice and learn-
ing. During the Object Naming Test, the subject named all
pictures correctly under each exporimentai condition. Hovj-
evoi", the time was considerably shorter during the second
experimental condition, the Cylert tr j al . The Recall Test
shov/ed little variation of results in any of the experimental
conditions. The Oral Reading Test produced similar test
times for all experimental conditions except the placebo
trial which took approximately twice as m.uch time. The Oral
Encoding Test demonstrated that with each successive exper-
imental condition, the subject responded with fewer words.
The tine was similar for all experimental conditions except
the placebo condition which was much shorter than the re-
maining trials. The results for Case I are presented graph-
ically in Figure 1, page 5l . The graph demonstrates the
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percentage of increase or decrease in pcrforraance from Ex-
periraental Condition I. For this subject, there was some-
suggestion thfit he was able to respond more rapidly while
under the influence of the experimental drug for tasks that
required concrete recognition responses to specific stimuli
but not for tasks requiring a formulated response to more
abstract stimuli. In general, hovjever, there vjas no suf-
ficient evidence to permit infoi'enccs regarding the effects
of the experimental drug.
Improvement
Percentage
change from
Initial
baseline
-r^ Regression
baseline Cylert Baseline Placebo Baseline
Figure 1. Case I. Percent of improvemGnt or regression
from the initial baseline on the test battery under pharma-
ceutical and additional baseline testing conditions.
52
Case II . The second subject, a 72 year old veteran,
suffered a cerebral vascular accident about tvjo years ago.
This subject Identified about half of the objects correctly
on the Sklar Object Identification Test under all conditions.
The time required for this task demonstrated improved re-
sponse time on each successive testing session which may be
due to a practice effect. On the Object Naming Test, Case
II increased his score with each successive trial. This may
have been due to the learning of the object's names. F\ir-
thermore, the time decreased as the successive conditions
wore presented. The first baseline condition took approxi-
mately three times as much time as the remaining four con-
ditions. The Recall Test demonstrated that vjith each suc-
cessive experimental condition, the subject responded with
more words. The Oral Reading Test was not undertaken at
this time because the task was too difficult for the subject.
The scoring on the Vocal Encoding Test indicated that the
placebo trial yielded the largest number of responses. Dur-
ing the magnesium pemoline condition, Case II made only one
half of the number of responses made in the placebo trial.
However, the time taken for this task v/as considerably'
shorter d\i.ring the magnesium pemoline administration than
for the other experimental conditions. The remaining ex-
perimental conditions required about tv/ice to three times
as much time to complete the task as the Cylert trial. The
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results for Case II are presented graphically in Figure 2
on page 5^-1-. These results are plotted as a percentage of
increase or decrease from Experimental Condition 1. For
this subject, there was some indication that he was able to
respond more rapidly v;hile receiving the experimental drug,
Cylert. The subject appeared to improve in the number of
responses to more concrete stimuli, hov;ever, the scores
varied sufficiently so as to suggest nothing more than
trends.
^-A
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Improvement
Baseline Cylert Baseline
Percentage
change from
initial
baseline
Regression
Placebo Baseline
Figure 2. Case II. Percent of improvement or regression
from the initial baseline on the test battery under pharma-
ceutical and additional baseline testing conditions.
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Case III . The third subject, a )4-9 years old male
veteran who suffered a cerebral vascular accident two and a
half years ago, presented the follov;ing pattern of results.
He obtained a high score on the Sklar Object Identification
Test, however, he did not achieve the possib].e total of 20
correct. The magnesium pemoline conditions yielded results
similar to experimental conditions one, three, and five.
During the placebo condition, the subject scored less cor-
rect responses. The time varied for each trial with the
magnesium pemoline condition requiring the most time. The
subsequent trials generally decreased in t?ie time required
for that task. On the Object Naming Test, Case III increased
his score with each successive trial. This may have been due
to the learning of the object's names. Furthermore, time
decreased as the conditions vrere presented, the first three
conditions requiring twice as much tnme as the last tv;o con-
ditions. The Recall Test was quite difficult for* this sub-
ject. He responded vjith two "h" words during the third
experimental condition. For the other experimental condi-
tions the subject gave no responses. The Oral Reading test
also yielded fevj responses from the subject. The subject
supplied no v/ords from the test paragraph during the first
trial; during the second ond final experimental conditions,
Case III read tvjo v;ords. During the p]_8cebo condition he
achieved his highest score of four words. His response time
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was approximately l\.0 seconds for each trial except the last
condition when his time vjas 7^4- seconds for two responses.
During the last test, the Vocal Encoding Test, the subject
provided no correct responses except for the final baseline
test when ho gave tv/o v/ords in 60 seconds. On the third
experimental condition, the subject attempted to verbalize
about one of the objects but coiald not produce the name.
The results for Case III are presented graphically in Figure
3 on page 57. 1'ho graph presents the scoi'es in percentages
of increase or decrease from Experimental Condition I.
There was no general pattern of responding established for
Case III. The magnesium pemoline condition indicated that
no improvement occurred as a result of its administration.
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Figure 3. Case III. Percent of improvement or regression
from the initial baseline on the test battery under pharmaceu-
tical and additional baseline testing conditions.
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Case IV , Case IV vjas a 9l[ years old male veteran who
had Parkinson's Disease. This fourth subject yielded these
results on the various tests. Case IV generally obtained a .
high score on the Sklar Object Identification Test. He
scored 20, the total possible, on the magnesium pemoline and
placebo conditions. On the other trials, the subject scored •
close to the possible total. The time factor varied a great
deal. The magnesium pemoline and placebo conditions dis-
played the shortest time taken for the Sklar Object Identi-
fication Test. The other conditions reqiiined a longer period
of time tVion the pharmaceutical conditions. The subject
scored thie maximum score under the vai'ious experimental con-
ditions of the Object Naming Test except the placebo condi-
tion with the score there being slightly be].ow the total
score. The first condition required the longest amount of
time for task completion. The remaining conditions took a
shorter amount of time. None of these scores varied greatly
among themselves. The results of the Recall Test showed
that Case IV supplied the least number of correct responses
during the magnesium pemoline condition. The remaining
trials demonstrated approximately three times as many re-
sponses. For the Oral Readi.ng Test, the subject averaged
one minute for the completion of the task under the various
conditions except the placebo trial which was not done by
the subject. The scoring of the Vocal Encoding Test
. 59
displnyed a rolstivcly consistent pattern except for the
placebo condition under wlrich the subject gave considerably
fewer responses tVion for the other testing conditions. The
time was similar for all conditions except the placebo con-
dition which was shorter as would be expected. This sub-
ject's performance is presented in Figure 1| on page 60
.
Case IV indicated a slight trend in improvement of response
time during the Cylert administration. In general, there is
not sufficient evidence to make a specific statement regard-
ing the effects of magnesium pemoline. . .•
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Figure I4.. Case IV. Percent of improvement or regression
from the initial baseline on the test battery under pharma-
ceutical and additional baseline testinc; conditions.
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Case V. Tho fifth subject was a ' I|-l year old male
veteran who sustained a serious brain injury from an acci-
dent. The accident occurred about six years ago. This case
performed as follov;s on the test battery. On the Sklar
Object Identification Tost, Case V scored tho maximum total
except on the third testing condition where he made one in-
correct response. The time required on this task demon-
strated improved response time on each sticcessive testing
session. Learning of the object's names due to pi'actice may
explain tho general improvement. Again, the subject scored
the total possible correct responses on the Object Naming
Test except for the third condition where he made one incor-
rect response. The time token to complete this test for the
various ti'ials was quite inconsistent. The first condition
took the longest period of time; the magnesium pemoline
testing trial decreased the time to less than half of that
taken for the first trial. Tho third condition test time
was similar to the Cylert condition test time. The placebo
condition I'eqiiired slightly more time than the magnesium
pemoline condition, and the last rjeriod vjas the shortest time
necessary for- this task. Thus, there vras again no marked
change in the performance score under the various conditions
and no pattern of Improvement in time vjas apparent to suggest
positive effects from practice. The Recall Test varied from
ten correct responses on the first trial to twenty correct
'.
'
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responses on the last trial. The Cylert condition had 19
correct responses. The third condition had fevjer correct
responses than the Cylert condition with the remaining con-
ditions indicating general improvement. The Oral Reading
Test indicated that Case V improved with each successive
experimental condition and decre.-ised the time required for
each task. The Vocal Encoding Test showed little variabil-
ity in the scoring. The first condition produced the fewest
correct responses; the Cylert and third trials had the
highest number of correct responses. The fourth and final
conditions had fevjer correct responses than the second and
third trials. The magnesium pemoline condition test time
was the longest of the various conditions. The other con-
ditions were similar in test time. Figure 3' on page 63,
presents the results for Case V. The scores are dernonstra ted
in percentages of increase or decrease from Experiment?)] Con-
dition I. This subject demonstrated a slight trend for im-
provement of response time during tl'ie administration of the
experimental drug. There was also a suggestion of enhanced
ability to supply more responses for the tasks requiring
abstract thinking. In respect to this observation, hovjever,
no generalization could be stated.
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Figure 3'. Case V. Percent of improvement or regression
from the initial baseline on the test battery under pharma-
ceutical and additional baseline testing conditions.
Case Vr
.
The sixth subject, a ^2 year old veteran
with Parkinson's Disease, performGd in the following manner
on the tests. Case VI identified correctly the 20 objects
on the Sklar Object Identification Test. The time taken
for the task varied slightly. The magnesium pemoline trial
and the third experimental condition trials required the
shortest amount of time taken for task completion. The
other conditions required a slightly longer period of time.
Again, the subject scored the total of 20 correct for each
experimental condition on the Object Naming Test. The time
taken for the task did not vary a great deal, the magnesium
pemoline trial requiring the least amount of test time. -
Howevoi', the remaining conditions wore only a few seconds
longer than the magnesium pemoline condition. The Recall
Test shovjed that the Cylert condition and the final condi-
tion yielded the most correct responses. The subject
achieved the lowest time for task completion for the Oral
Reading Test during the Cylert trial test time. The first
condition test time was slightly longer than the magnesium
pemoline condition. The remaining conditions required ap-
proximately twice as much time as the Cylert condition. The
subject obtained a fairly consistent score for the Vocal
Encoding Test. The time variable, however, was rather in-
consistent. The magnesium pemoline and the placebo condi-
tions required the least amount of time. Conditions one
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three, and five took 8 slightly longer period of time to
complete the task. This subject's results are presented
graphically in Figure 6 on page 66. The scores are pre-
sented in percentages of increase and decrease from Exper-
imental Condition 1. Case VI demonstrated some increased
ability to respond more rapidiy during the administration
of the magnesium pemoline. Again, however, no generaliza-
tion could be made from this observation.
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Improvement
Percentage
change from
initial
basel ine
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Basel in e Oylert Baseline Placebo Baseline
Figure 6. Case VI. Percent of improvement or regression
from the initial baseline on the test battery under pharma-
ceutjcal and additional baseline testing conditions.
67
Tests
Sklar Obje ct Identi fication Test. The Sklar Object
Identification scores did not shoi^J any general pattern of
improveraent during the drug administration. The time re-
quired for this task under the magnesium pemoline condition
generally required a shorter time period than for the first
baseline condition. The subsequent time improve-rient for the
following experimental conditions possibly may be explained
as a function of a practice effect. Figure 7, page 68,
presents percentage change of each subject's score to the
Sklar Object Identification Test during the five conditions.
Figure 8, page 69, presents the percentage change of each
subject's response time required for the task completion.
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Object Naming Test . The Object Nartiing Test did not
indicate any general pattern of ImproveTient across subjects
during the rnagneslu:n pemoline administration. The subjects'
baseline scores, in all cases, were the same as the Cylert
scores. In each case, hoxvever, the Cylert condition re-
quired less time than the first baseline condition. The
subjects' scores varied, with Cases II, IV, and V presenting
a more notable time decrease than Cases I, III, and VI.
Figures 9 and 10, pages 71 and 72, graphically demonstrate
the raw score change and time change percentages of each
subject from Experimental Condition I.
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Figure 9. Percent of numerical improvement or regression
from the initial baseline for all subject on the Object Iden-
tification Test.
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Recall Test . The Recall Test, completed by five sub-
jects, demonstrated no pattern In the results that v/ere ob-
tained. Two subjects improved during the magnesium pemoline
administration, one subject maintained his baseline rate;
the remaining tvjo subjects decreased in the recall of "h"
words. Figure ].l, page 7k, graphically presents the results
on this task.
ih
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Figure 11. Percent of mirnerical improvement or regres-
sion from the initial baseline for the subjects that partic-
ipated in the Recall Test
.
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Oral Reading Test . The Oral Reading Test presented
only one instance where the subject improved during the
Cylert administration, however, two su_bjects did not par-
ticipate in the task. The time differences between Exper-
imental Condition I and Experimental Condition II wei'e
relatively small. During the remaining experimental condi-
tions, no pattern could be established. On page 76, Figure
12 graphically presents the results of each subject on the
test.
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Vocal Encod inp; Test . The Vocal Encoding Test demon-
strated that Cases II, IV, and V Improved their numerical
scores during the Cylcrt administration. However, this
score v/as consistently improved during subsequent conditions.
Cases I and VI decreosed their scores during the drug admin-
istration, and Case III did not participate in the test.
The test time indic;itGd a slight trend for improvement dur-
ing the Cylert condition, but no pattern could be established
Figures 13 and IJ4. on psges 78 and 79, graphically display the
percentages of numerical response and test time change for
each subject
.
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Chap ter Summary
This chapter presented the performance results of
central nervous system di. sordered patients on the tests
employed in this investigation under five experimental con-
ditions. The results were presented in respect to each sub-
ject and for each test.
In general, the performance of the subjects on the
selected tests varied randomly v;1th the experimental condi-
tions which suggests that any differences among the experi-
mental conditions occurred by chance. This would indicate
that magnesium pemoline does not have any specific influence
on central nervous system disoi'^dered patients as measured by
the test battery employed in this investigation.
•?I?
CHAPTEI"? V
SUMMARY AND CONCLTTSIONS
Man's central nervous system holds a vital role in
his ability to speak. This advanced central nervous systeoi
has made the complex speaking process possible. Without
this higher nervous system, man viould be completely incap-
able of producing meaningful speech. Since tVie central
nervous system controls the body functions that produce
speech, agents acting upon the central nervous system could
be expected to effect speech. Abbott Laboratories have in-
troduced a chemical compound magnesium pemoline, as a central
nervoias system stimulant. It has been observed by employees
at the Veteran Administration Hospital in Topeka, Kansas
that the anticijiated effect seemed to be present in the
speecVi of central nervous system disordered patients v;hile
receiving magnesium pemoline during a pilot study. These
informa] observations Viave been cited by several people v/ho
worked closely with these patients and v;ero generally re-
garded as enhancing speech. Chapter I stated that the pur-
pose of the present study was to test experimentally the
effects of magnesium pemoline in central nervous system dis-
ordered patients on the expressive verbal aspects of speech.
The study was concerned also with the rehabilitative value
of magnesium pemoline.
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Investigators recently have concentrated a substan-
tial amount of research on the effects of drugs on verbal
output. Selected studies from the areas of hallucinogenic
drugs, stimulants, central nervous system stimulants, and
specifically, magnesium pemoline v;ere reviewed in Chapter
II.
Chapter III described the subjects, experimental
design, test events, and the testing procedures that were
employed for this investigation. Five experimental condi-
tions vjcre established to study the effects of magnesium
pemoline. Experimental Conditions I, III, and V v/ere devel-
oped to investigate baseline information. Experimental Con-
ditions II and IV were established to investigate the effect
of magnesium pemoline and the placebo on the speech of cen-
tral nervous system disordered patients.
In Chapter IV, the results of the study were pre-
sented according to subjects, tests, and experimental con-
ditions. The performances of the subjects on the selected
tests varied randomly v;ith the experimental conditions. In
respect to the findings of the present study, it may be con-
cluded either that (1) magnesium pemoline did not have any
specific influence on the speech of central nervous system
disordered patients as measured by the test battery employed
in this investigation, or (2) if specific influences were
present, the test battery employed was not adequate for
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demonstrating these effects. " . '
Although some researchers have found Instances of
improved performance with magnesium pemoline, none of these
experiments furnished evidence that this effect was reliable
under the conditions of a double-blind study. Therefore,
whatever influence this drug may have on brain metabolism,
its use as a pharmacological remedy for imi)roving speech in
central nervous system disordered patients does not appear
promising. Hov/ever, if observations of improved speaking
ability from persons working with this drug persist, then
further investigation of this drug should be undertaken.
The present study may not have indicated the positive ef-
fects that magnesium pemoline may possess. Piarthei^ investi-
gation to study the effects of magnesium pemoline could be
done employing different measures that may possibly better
quantify the apparent speech differences. Spectrographlc
analysis of tVie voice quality would appear to be one pos-
sible direction for study. Other types of measures of ex-
pressive language abilities, such as mean length of response,
would perhaps also be more fruitful in quantifying any real
djJ'feroncos due to the action of pharmaceutical agents.
Should future research contraindicate the result of the
present study, this finding would be welcome by the reha-
bilitation vjorkers concerned with central nervous system
disordered patients.
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Six adult patients of the neurology service at the
Veteran's Administration Hospital who exhibited some speech
difficulty associated vjith a history of nervous system damage
or injury were selected for this study.
Case 1
General Information:
Case 1, a 60 year old Negro male, is a former mainte-
nance worker. He was employed until his cerebral vascular
accident on September 28, 19^6.
Medical Diagnosis:
1. Cerebral thrombosis duo to arteriosclerosis vessel
indeterminate with riglit hemiparesis and focal motor sei-
zures.
2. Chronic brain syndrome associated with arterio-
sclorosi s
.
Medical Prognosis:
The prognosis is favorable and rehabilitation work is
recommended
.
Case 2
General Information:
Case 2, a 72 year old male veteran, is a former
foundry vjorker. This subject has a long history of various
•'
92
earlier illnesses
.
Medical Diagnosis:
1. Arteriosclerotic disease, generalized, moderate
to severe with cardiac involvement and peripheral arterial
disease
.
2. Chronic brain syndrome, secondary to cerebral
vascular accident, with right sided hemiplegia and mild left-
sided hemiparesis and urinary incontinence.
3. Gil tract infection, chronic.
!(.. Mild emphysema with intermittent mild pulmonary
tract infection of a peripheral nature.
Medical Prognosis:
The prognosis for this patient is generally poor.
Case 3
General Information:
Case 3 suffered a cerebral vascular accident on
October 31, 196^. Previously, he was self-employed as a
grocer in Melvern, Kansas. This subject is [|.9 years old.
Me d i c a ]_ D i a gn o s i s
:
1 . Left internal carotid artery occlusion, manifested
by a flaccid right-sided paralysis, aphasia, paresis of right
conjugate gaze, right lov/er facial v^eakness.
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Medical Prognosis:
The prognosis is exceedingly limited for any further
degree of improvement of his muscular vjeakness or speech.
However, at the present time he has the capacity to perform
self-care activities.
Case [).
'
General Information:
Case four j.s a 9^1^ year old male veteran vjho before
retirement v;as employed as a moat inspector. The subject
was admitted to the Veteran Hospital in February 1967.
Medical Diagnosis:
1. Basal artery insufficiency manifested by weakness
in the left arm and leg, difficulty swallov/ing, chewing, and
hoarseness
.
2. Parkinson's Disease, likely on a atherosclerotic
basis.
3. Acute bronchopneumonia, treated.
l\.. Prostatic hypertrophy, benign, treated.
Medical Prognosis:
The prognosis is uncertain as manifested by the
patient's unpredictable course early in hospitalization.
9I^
Case 5'
General Information:
Case five suffered a severe head injury in a car
accident on July 7, 1962. He is a I4.I year old male veteran.
Medical Information:
1. Post-traumatic encephalopathy chronic, severe,
manifested by severe degree of organic dementia, expressive
aphasia, some receptive aphasia, ataxia, and muscular weak-
ness.
Medical Prognosis:
The prognosis for this patient is genei'ally fair.
The recommendation is for him to receive continuous treatment
on an oxitpatient basis.
Case 6
General Informati.on:
The sixtVi case is a 3'2 year old retired Army Major.
This subject suffers from paralysis agitans.
Medical Diagnosis:
1. Paralysis agitans (Parkinson's Disease), chronic,
bilateral, and severe.
2. Acute lumbosacral strain, associated with degen-
erative disc disease.
9^
Medical Prognosis:
The prognosis for this subject is fair in regard to
longevity but poor in regard for recovery.
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The chemical compound, m.agnesiura pemoline, produced
by Abbott Laboratories under the trade name Cylcrt, has been
introduced as a central nervous system stimulant. Cylert is
a combination of pemoline and magnesium hydroxide. Although
the specific action of this compound has not been determined,
it apparently stimulates the specific activity of brain
nuclear RKA, v;hich in turn, stimulates the central nervous
system. Since the central nervous system controls the abil-
ity to produce meaningful speech, the enhancement or stimu-
la.tion of the centi'al nervous system should faciDitate speech.
Recent research at the Veteran's Administration Hos-
pital in Topeka, Kansas has been concerned with magnesium
pemoline as an enhancer of memory and learning in brain
damaged patients. Preliminary evidence has suggested t?iat
magnesium pemoline increases the memory and ] earning span of
some of these patients. Therefore, the purpose of the pres-
ent study vjas to test experimentally the effects of magnesium
pemoline in central nervous system disordered patients on the
expressive verbal aspects of speech.
Six adult patients of the neurology service at the
Veteran's Administration Hospital in Topeka, Kansas, who
exhibited some speech difficulty associated v;ith a history
of nervoiis system damage or injury, v/ere selected for this
study. Five experimental conditions were established to
study the effects of magnesium pemoline on the speech of
2central nervous system disordered patients. The Experimental
Conditions I, III, and V vjere developed to establish baseline
information and to study the effects of learning and practice.
The purpose of Experimental Conditions II and IV, pharmaceu-
tical conditions, was to establish and investigate the
effects of magnesium pemoline and the effects of a placebo
on speech. V/hen a subject was receiving magnesium pemoline,
the effects of the drug were measured by comparing the drug
condition to the baseline conditions or to the pD.acobo con-
dition.
The performance of the subjects on the selected tests
appeared to very randomly vjith the experimental conditions
vj-hich suggests that any differences among the experimental
conditions may have occurred by chance. This would indicate
that magnesium pemoline does not have any specific influence
on central nervous system disordered patients, as measured
by the test battery employed in this investigation. However,
the test battery employed in the present study may have been
inadequate to indicate any positive effects that magnesium
pemoline may possess. Further investigation to study the
effects of magnesium pemoline, employing different measures,
may possibly better demonstrate any differences in speaking
ability that may exist.
